Cargando…

The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer

BACKGROUND: Advanced gastric cancer sometimes causes macroscopic serosal change (MSC) due to direct invasion or inflammation. However, the prognostic significance of MSC remains unclear. METHODS: A total of 1410 patients who had been diagnosed with deeper-than-pathological-T2 gastric cancer and unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Yura, Masahiro, Yoshikawa, Takaki, Wada, Takeyuki, Otsuki, Sho, Hayashi, Tsutomu, Yamagata, Yukinori, Katai, Hitoshi, Nishida, Toshirou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465694/
https://www.ncbi.nlm.nih.gov/pubmed/34563160
http://dx.doi.org/10.1186/s12885-021-08767-8
_version_ 1784572941971750912
author Yura, Masahiro
Yoshikawa, Takaki
Wada, Takeyuki
Otsuki, Sho
Hayashi, Tsutomu
Yamagata, Yukinori
Katai, Hitoshi
Nishida, Toshirou
author_facet Yura, Masahiro
Yoshikawa, Takaki
Wada, Takeyuki
Otsuki, Sho
Hayashi, Tsutomu
Yamagata, Yukinori
Katai, Hitoshi
Nishida, Toshirou
author_sort Yura, Masahiro
collection PubMed
description BACKGROUND: Advanced gastric cancer sometimes causes macroscopic serosal change (MSC) due to direct invasion or inflammation. However, the prognostic significance of MSC remains unclear. METHODS: A total of 1410 patients who had been diagnosed with deeper-than-pathological-T2 gastric cancer and undergone R0 gastrectomy with lymph node dissection at the National Cancer Center Hospital during January 2000 and December 2012 were restrospectively reviewed. RESULTS: MSC was not found in 108 of the 506 patients with pathological T4a (21.3%), whereas it was detected in 250 of the 904 patients with pathological T2-T3 (27.7%). The sensitivity, specificity and accuracy for diagnosing pathological serosa exposed (SE) by MSC were 78.7, 72.3 and 74.6%, respectively. The MSC-positive cases had a worse 5-year overall survival (OS) than the MSC-negative cases in pT3 (72.9% vs. 84.3%, p = 0.001), pT4a (56.2% vs. 73.4%, p = 0.001), pStageIIB (76.0% vs. 88.4%, p = 0.005), pStageIIIA (63.4% vs. 75.6%, p = 0.019), pStageIIIB (53.6% vs. 69.2%, p = 0.029) and pStage IIIC (27.6% vs. 50.0%, p = 0.062). A multivariate analysis showed that MSC was a significant independent predictor for the OS (hazard ratio [HR]: 1.587, 95%CI 1.209–2.083, p = 0.001) along with the tumor depth (HR: 7.742, 95%CI: 2.935–20.421, p < 0.001), nodal status (HR:5.783, 95% CI 3.985–8.391, p < 0.001) and age (HR:2.382, 95%CI: 1.918–2.957, p < 0.001). Peritoneal recurrence rates were higher in the MSC-positive cases than in the MSC-negative cases at each pT stage. CONCLUSIONS: In this study, the MSC was one of the independent prognostic factors in patients with resectable locally advanced gastric cancer.
format Online
Article
Text
id pubmed-8465694
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84656942021-09-27 The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer Yura, Masahiro Yoshikawa, Takaki Wada, Takeyuki Otsuki, Sho Hayashi, Tsutomu Yamagata, Yukinori Katai, Hitoshi Nishida, Toshirou BMC Cancer Research Article BACKGROUND: Advanced gastric cancer sometimes causes macroscopic serosal change (MSC) due to direct invasion or inflammation. However, the prognostic significance of MSC remains unclear. METHODS: A total of 1410 patients who had been diagnosed with deeper-than-pathological-T2 gastric cancer and undergone R0 gastrectomy with lymph node dissection at the National Cancer Center Hospital during January 2000 and December 2012 were restrospectively reviewed. RESULTS: MSC was not found in 108 of the 506 patients with pathological T4a (21.3%), whereas it was detected in 250 of the 904 patients with pathological T2-T3 (27.7%). The sensitivity, specificity and accuracy for diagnosing pathological serosa exposed (SE) by MSC were 78.7, 72.3 and 74.6%, respectively. The MSC-positive cases had a worse 5-year overall survival (OS) than the MSC-negative cases in pT3 (72.9% vs. 84.3%, p = 0.001), pT4a (56.2% vs. 73.4%, p = 0.001), pStageIIB (76.0% vs. 88.4%, p = 0.005), pStageIIIA (63.4% vs. 75.6%, p = 0.019), pStageIIIB (53.6% vs. 69.2%, p = 0.029) and pStage IIIC (27.6% vs. 50.0%, p = 0.062). A multivariate analysis showed that MSC was a significant independent predictor for the OS (hazard ratio [HR]: 1.587, 95%CI 1.209–2.083, p = 0.001) along with the tumor depth (HR: 7.742, 95%CI: 2.935–20.421, p < 0.001), nodal status (HR:5.783, 95% CI 3.985–8.391, p < 0.001) and age (HR:2.382, 95%CI: 1.918–2.957, p < 0.001). Peritoneal recurrence rates were higher in the MSC-positive cases than in the MSC-negative cases at each pT stage. CONCLUSIONS: In this study, the MSC was one of the independent prognostic factors in patients with resectable locally advanced gastric cancer. BioMed Central 2021-09-25 /pmc/articles/PMC8465694/ /pubmed/34563160 http://dx.doi.org/10.1186/s12885-021-08767-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yura, Masahiro
Yoshikawa, Takaki
Wada, Takeyuki
Otsuki, Sho
Hayashi, Tsutomu
Yamagata, Yukinori
Katai, Hitoshi
Nishida, Toshirou
The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title_full The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title_fullStr The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title_full_unstemmed The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title_short The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
title_sort prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465694/
https://www.ncbi.nlm.nih.gov/pubmed/34563160
http://dx.doi.org/10.1186/s12885-021-08767-8
work_keys_str_mv AT yuramasahiro theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT yoshikawatakaki theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT wadatakeyuki theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT otsukisho theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT hayashitsutomu theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT yamagatayukinori theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT kataihitoshi theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT nishidatoshirou theprognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT yuramasahiro prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT yoshikawatakaki prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT wadatakeyuki prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT otsukisho prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT hayashitsutomu prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT yamagatayukinori prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT kataihitoshi prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer
AT nishidatoshirou prognosticimpactofmacroscopicserosalchangeonresectableadvancedgastriccancer